686 related articles for article (PubMed ID: 10566646)
21. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients.
Savagner F; Rodien P; Reynier P; Rohmer V; Bigorgne JC; Malthiery Y
J Clin Endocrinol Metab; 2002 Feb; 87(2):635-9. PubMed ID: 11836297
[TBL] [Abstract][Full Text] [Related]
22. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
24. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.
Grammatopoulos D; Elliott Y; Smith SC; Brown I; Grieve RJ; Hillhouse EW; Levine MA; Ringel MD
Mol Pathol; 2003 Jun; 56(3):162-6. PubMed ID: 12782763
[TBL] [Abstract][Full Text] [Related]
25. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer.
Lombardi CP; Bossola M; Princi P; Boscherini M; La Torre G; Raffaelli M; Traini E; Salvatori M; Pontecorvi A; Bellantone R
Am J Surg; 2008 Sep; 196(3):326-32. PubMed ID: 18614150
[TBL] [Abstract][Full Text] [Related]
26. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
27. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
28. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
29. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
30. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
[TBL] [Abstract][Full Text] [Related]
31. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
32. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
34. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
35. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
36. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
37. [Serum thyroglobulin in the diagnosis of metastases of differentiated thyroid cancer. Effect of suppressive thyroid hormone substitution on the diagnostic accuracy of thyroglobulin values].
Müller-Gärtner HW; Schneider C; Tempel MT
Nuklearmedizin; 1986 Oct; 25(5):194-200. PubMed ID: 3797259
[TBL] [Abstract][Full Text] [Related]
38. Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma.
do Rosário PW; Fagundes TA; Maia FF; Franco AC; Figueiredo MB; Purisch S
J Ultrasound Med; 2004 Jul; 23(7):915-20; quiz 921-2. PubMed ID: 15292559
[TBL] [Abstract][Full Text] [Related]
39. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
40. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study.
Bellantone R; Lombardi CP; Bossola M; Ferrante A; Princi P; Boscherini M; Maussier L; Salvatori M; Rufini V; Reale F; Romano L; Tallini G; Zelano G; Pontecorvi A
Cancer; 2001 Nov; 92(9):2273-9. PubMed ID: 11745281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
